Current Use of Testosterone Therapy in LGBTQ Populations

Overview

Journal Int J Impot Res

Specialties Reproductive Medicine
Urology

Date 2021 Nov 24

PMID 34815551

Citations 1

Authors

A N Tijerina

A V Srivastava

V R Patel

E C Osterberg

Affiliations

Soon will be listed here.

Abstract

Testosterone therapy (TT) is a type of gender-affirming hormone therapy (GAHT) in lesbian, gay, bisexual, transgender, and genderqueer (LGBTQ) populations for gender dysphoria (GD), body uneasiness, and sexual dysfunction. The physical and physiological effects of TT vary widely depending on the dosing regimen and duration of treatment. An individualized approach prioritizing patient-specific desired effects in the context of pre-existing characteristics and health history is strongly recommended. Although TT is an effective treatment for many patients, there has been an increase in the illegitimate acquisition of TT in recent years. Non-judicious prescribing and lack of physician surveillance increases the risk of unintended side effects and potential serious health consequences.

Citing Articles

Advancements in the evaluation and treatment for Testosterone Deficiency.

Kresch E, Patel P, Ramasamy R Int J Impot Res. 2022; 34(7):621-622.

PMID: 35388179 DOI: 10.1038/s41443-022-00570-8.

References

Nieschlag E, Nieschlag S . ENDOCRINE HISTORY: The history of discovery, synthesis and development of testosterone for clinical use. Eur J Endocrinol. 2019; 180(6):R201-R212. DOI: 10.1530/EJE-19-0071. View

Rastrelli G, Corona G, Maggi M . Testosterone and sexual function in men. Maturitas. 2018; 112:46-52. DOI: 10.1016/j.maturitas.2018.04.004. View

Tsametis C, Isidori A . Testosterone replacement therapy: For whom, when and how?. Metabolism. 2018; 86:69-78. DOI: 10.1016/j.metabol.2018.03.007. View

Radix A . Hormone Therapy for Transgender Adults. Urol Clin North Am. 2019; 46(4):467-473. DOI: 10.1016/j.ucl.2019.07.001. View

Defreyne J, TSjoen G . Transmasculine Hormone Therapy. Endocrinol Metab Clin North Am. 2019; 48(2):357-375. DOI: 10.1016/j.ecl.2019.01.004. View

Nieschlag E, Nieschlag S . Testosterone deficiency: a historical perspective. Asian J Androl. 2014; 16(2):161-8. PMC: 3955324. DOI: 10.4103/1008-682X.122358. View

Morgentaler A, Traish A . The History of Testosterone and the Evolution of its Therapeutic Potential. Sex Med Rev. 2018; 8(2):286-296. DOI: 10.1016/j.sxmr.2018.03.002. View

Gagliano-Juca T, Basaria S . Testosterone replacement therapy and cardiovascular risk. Nat Rev Cardiol. 2019; 16(9):555-574. DOI: 10.1038/s41569-019-0211-4. View

Bhasin S, Cunningham G, Hayes F, Matsumoto A, Snyder P, Swerdloff R . Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95(6):2536-59. DOI: 10.1210/jc.2009-2354. View

10.

Mulhall J, Trost L, Brannigan R, Kurtz E, Redmon J, Chiles K . Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018; 200(2):423-432. DOI: 10.1016/j.juro.2018.03.115. View

11.

Bhasin S, Enzlin P, Coviello A, Basson R . Sexual dysfunction in men and women with endocrine disorders. Lancet. 2007; 369(9561):597-611. DOI: 10.1016/S0140-6736(07)60280-3. View

12.

Wang C, Nieschlag E, Swerdloff R, Behre H, Hellstrom W, Gooren L . Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008; 159(5):507-14. PMC: 2754376. DOI: 10.1530/EJE-08-0601. View

13.

Spitzer M, Huang G, Basaria S, Travison T, Bhasin S . Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol. 2013; 9(7):414-24. DOI: 10.1038/nrendo.2013.73. View

14.

Snyder P, Bhasin S, Cunningham G, Matsumoto A, Stephens-Shields A, Cauley J . Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016; 374(7):611-24. PMC: 5209754. DOI: 10.1056/NEJMoa1506119. View

15.

Cunningham G, Stephens-Shields A, Rosen R, Wang C, Bhasin S, Matsumoto A . Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels. J Clin Endocrinol Metab. 2016; 101(8):3096-104. PMC: 4971331. DOI: 10.1210/jc.2016-1645. View

16.

Roy C, Snyder P, Stephens-Shields A, Artz A, Bhasin S, Cohen H . Association of Testosterone Levels With Anemia in Older Men: A Controlled Clinical Trial. JAMA Intern Med. 2017; 177(4):480-490. PMC: 5433757. DOI: 10.1001/jamainternmed.2016.9540. View

17.

Dimopoulou C, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Perez-Lopez F . EMAS position statement: Testosterone replacement therapy in the aging male‏. Maturitas. 2015; 84:94-9. DOI: 10.1016/j.maturitas.2015.11.003. View

18.

Handelsman D . Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse. Med J Aust. 2013; 199(8):548-51. DOI: 10.5694/mja13.10111. View

19.

Baillargeon J, Urban R, Ottenbacher K, Pierson K, Goodwin J . Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013; 173(15):1465-6. PMC: 4100547. DOI: 10.1001/jamainternmed.2013.6895. View

20.

Purcell D, Wolitski R, Hoff C, Parsons J, Woods W, Halkitis P . Predictors of the use of viagra, testosterone, and antidepressants among HIV-seropositive gay and bisexual men. AIDS. 2005; 19 Suppl 1:S57-66. DOI: 10.1097/01.aids.0000167352.08127.76. View